why choose us

First received: November 15, 2022

Clinical Trial: Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Central Nervous System Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS Lymphoma

Brief Summary: This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with primary central nervous system (CNS) lymphoma.CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.T cells are taken from a patient's blood.Then the gene for a special receptor that binds to a certain protein,…

Read more